Evaluation of the efficacy and dose-response relationship of dexibuprofen (S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index

Singer, F.; Mayrhofer, F.; Klein, G; Hawel, R; Kollenz, C J

doi:10.5414/cpp38015

Cited by 23 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the present clinical trial confirm at least noninferiority of both dexibuprofen doses compared to conventional ibuprofen at a common dose for the investigated indication. These results are supported by other clinical trials demonstrating noninferiority of dexibuprofen compared to the double dose of conventional ibuprofen in different indications [14,[16][17][18] . The descriptive analyses of the additionally assessed pain criteria support the results of the confirmatory analyses.…”

Section: Discussionsupporting

confidence: 78%

“…The presence of R -ibuprofen decreased the potency of S -ibuprofen much more than theoretically expected [25] . Bridging studies versus conventional ibuprofen and studies versus other NSAIDs including celecoxib confirm the good relative efficacy and tolerability profile of dexibuprofen [14,[16][17][18] . Results from clinical trials demonstrate that at a dose ratio of 0.5: 1 dexibuprofen is at least equally effective and safe as conventional ibuprofen [14,[16][17][18] .…”

Section: Discussionmentioning

confidence: 99%

“…In clinical trials and in postmarketing surveillance studies, more than 12,000 patients were treated with dexibuprofen in a special crystal form. The results of these trials show that a dose ratio of 0.5: 1 of dexibuprofen versus conventional ibuprofen provided adequate analgesia [14,[16][17][18] .…”

mentioning

confidence: 99%

See 2 more Smart Citations

ADIDAC Trial: Analgesia with Dexibuprofen versus Ibuprofen in Patients Suffering from Primary Dysmenorrhea: A Crossover Trial

Kollenz

Phleps

Kaehler³

2008

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: Primary dysmenorrhea is estimated to affect 40–50% of menstruating young women. Methods: Randomized, double-blind, 3-cycle crossover, active-controlled clinical trial conducted in 102 outpatients. Results: 102 patients entered the study and 77 were eligible for analyses. The mean (SD) age was 31.1 (7.0) years, and the mean cycle duration was 28.1 days (1.89) with a mean menstrual phase of 5.3 days (1.28). 40.26% of patients reported moderate pain from dysmenorrhea, and the remaining 59.74% reported severe pain. Compared to ibuprofen 400 mg, both dexibuprofen doses (200 and 300 mg) showed a trend towards superiority for sum of pain intensity difference (sum of PID), PID and total pain relief. Furthermore, dexibuprofen 200 mg had a faster onset of action compared to the double dose of ibuprofen (p = 0.035). A dose-effect relationship could be demonstrated for dexibuprofen in this visceral pain model. Tolerability was similar across all treatments. Conclusions: In patients experiencing acute visceral pain as a result of primary dysmenorrhea, dexibuprofen was associated with a dose-dependent effective analgesia; this effect was at least equivalent to that of the double dose of ibuprofen. With its lower body-loading dose, dexibuprofen expands the alternatives available to treat this condition.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ADIDAC Trial: Analgesia with Dexibuprofen versus Ibuprofen in Patients Suffering from Primary Dysmenorrhea: A Crossover Trial

Kollenz

Phleps

Kaehler³

2008

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Among these are rheumatic and other musculoskeletal conditions (Boardman et al 1967;Owen-Smith and Burry 1972;Altman 1984;Dieppe et al 1989;Haase and Fischer 1991;Bliddel et al 2000;Singer et al 2000;Buchanan and Kean 2002), dental pain and surgery, dysmenorrhoea, upper respiratory tract conditions (colds, influenza), headaches, accidental sports injuries and surgical conditions (Nørholt et al 1998;Kean et al 1999;Dionne and Cooper 1999a, b;Rainsford 1999c;Hersh et al 2000a, b;Steen Law et al 2000;Doyle et al 2002;Beaver 2003;Dalton and Schweinle 2006;Sachs 2005;McQuay and Moore 2006;Eccles 2006;Verhagen et al 2006;Huber and Terezhalmi 2006). It is not the purpose here to review the evidence in extenso about the clinical efficacy in various painful states since this is well established from over 40 years of research and applications of ibuprofen in the treatment of these conditions (Kean et al 1999;Rainsford 1999c).…”

Section: Relief Of Pain Inflammation and Fevermentioning

confidence: 98%

Ibuprofen: pharmacology, efficacy and safety

2009

View full text Add to dashboard Cite

This assessment of the safety and benefits of ibuprofen can be summarized thus: (1) Ibuprofen at OTC doses has low possibilities of serious GI events, and little prospect of developing renal and associated CV events. Ibuprofen OTC does not represent a risk for developing liver injury especially the irreversible liver damage observed with paracetamol and the occasional liver reactions from aspirin. (2) The pharmacokinetic properties of ibuprofen, especially the short plasma half-life of elimination, lack of development of pathologically related metabolites (e.g. covalent modification of liver proteins by the quinine-imine metabolite of paracetamol or irreversible acetylation of biomolecules by aspirin) are support for the view that these pharmacokinetic and notably metabolic effects of ibuprofen favour its low toxic potential. (3) The multiple actions of ibuprofen in controlling inflammation combine with moderate inhibition of COX-1 and COX-2 and low residence time of the drug in the body may account for the low GI, CV and renal risks from ibuprofen, especially at OTC doses.

show abstract

“…Bodily pain and functional disorders associated with AORC greatly reduce the patient's quality of life (Reginster, 2002). Relieving pain suffered by the patient is the single most important goal that the health care practitioner wishes to achieve (Singer et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of Devil's Claw tablets in patients with general rheumatic disorders

Warnock¹,

McBean²,

Suter³

et al. 2007

Phytotherapy Research

View full text Add to dashboard Cite

Arthritis and other rheumatic conditions (AORC) are the leading cause of disability, are associated with poor quality of life and incur considerable direct and indirect costs. It is considered that the instance of AORC will continue to increase. To assess the effectiveness, safety and tolerability of Harpagophytum (Bioforce) in the treatment of AORC, a single group open study of 8 weeks duration (259 patients) was performed in the United Kingdom. Effectiveness was assessed by numeric rating scales, the Western Ontario and McMasters Universities Osteoarthritis (WOMAC) Index and the Algofunctional Hand Osteoarthritis Index. Tolerance was measured by a numeric rating scale and safety by self-reporting, blood analysis and liver function tests. Quality of life was measured by SF-12 questionnaire. There were statistically significant (p < 0.0001) improvements in patient assessment of global pain, stiffness and function. There were also statistically significant reductions in mean pain scores for hand, wrist, elbow, shoulder, hip, knee and back pain. Quality of life measurements (SF-12) were significantly increased from baseline and 60% patients either reduced or stopped concomitant pain medication. Harpagophytum is an effective and well-tolerated serious treatment option for mild to moderate degenerative rheumatic disorders providing improved quality of life measure.

show abstract

Evaluation of the efficacy and dose-response relationship of dexibuprofen (S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index

Cited by 23 publications

References 0 publications

ADIDAC Trial: Analgesia with Dexibuprofen versus Ibuprofen in Patients Suffering from Primary Dysmenorrhea: A Crossover Trial

ADIDAC Trial: Analgesia with Dexibuprofen versus Ibuprofen in Patients Suffering from Primary Dysmenorrhea: A Crossover Trial

Ibuprofen: pharmacology, efficacy and safety

Effectiveness and safety of Devil's Claw tablets in patients with general rheumatic disorders

Contact Info

Product

Resources

About